Beneficial Effects on Skeletal Muscle of the Angiotensin II Type 1 Receptor Blocker Irbesartan in Experimental
Heart Failure H eart failure is characterized by a decreased exercise capacity with early occurrence of fatigue and dyspnea. These symptoms are partially due to a skeletal muscle myopathy, with atrophy and a shift from the "slow" fatigue resistant type I fibers to the more fatigable "fast" type II fibers. 1, 2 This is evident in humans and in animal models of congestive heart failure (CHF), in which we also found a correlation between the severity of the syndrome and skeletal muscle myosin heavy chain (MHC) composition. [3] [4] [5] The origin of this myopathy is not yet clear, although its specificity has been hypothesized. 3, 6 Similarly, the link between exercise capacity and endurance, muscle atrophy, and changes in fiber type are still ill-defined.
We recently showed in rats with CHF 7 that the degree of muscle atrophy correlates with the magnitude of apoptosis and the severity of CHF and is accompanied by elevated plasma levels of tumor necrosis factor-␣ (TNF␣). In humans, muscle bulk loss, one of the most important determinants of exercise capacity, 2 is equally secondary to myocyte apoptosis. 8 Apoptosis is involved in myocyte loss both in CHF and in cardiomyopathies. 9 It has been suggested that in the heart, apoptosis can be triggered by angiotensin II (AngII) or cytokines, such as TNF␣. 10, 11 However, it is not clear whether AngII determines apoptosis via type 1 (AT 1 ) or type 2 (AT 2 ) receptors. Many authors have suggested that AT 2 receptor stimulation brings about apoptosis. 12, 13 In contrast, losartan, an AT 1 receptor blocker, and captopril, an ACE inhibitor, can block apoptosis both in vitro (isolated stretched myocytes) and in vivo (spontaneously hypertensive rats with CHF). 14, 15 All these results are intriguing and, in this article, we tested the hypothesis that AT 1 blockade with irbesartan can prevent apoptosis and skeletal muscle atrophy.
Methods Experimental Model
We studied 36 male Sprague-Dawley rats weighing 80 to 100 g that had CHF induced by monocrotaline. This alkaloid produces severe pulmonary hypertension followed by right ventricular (RV) failure 16 without itself inducing changes in skeletal muscle MHC composition and apoptosis. 7 Monocrotaline was injected intraperitoneally in the rats at a dose of 30 mg/kg. The rats were then divided into 3 groups.
After 2 weeks, 18 of the 36 rats had 7 mg · kg -1 · d -1 irbesartan delivered through Alzet osmotic minipumps. Irbesartan 250 mg was solubilized in 3.75 mL of 0.19 mol/L KOH at room temperature and sonicated for 1 minute; 0.75 mL of 50 mmol/L Tris was added and neutralized at pH 8. This is the method used for intravenous preparations. 17 The second group consisted of 10 rats (of the 36) that were treated with 2 mg · kg -1 · d -1 nifedipine, which was given in drinking water. Rats were kept in single cages, and the amount of water drunk was measured daily. The final 8 rats had a salinedelivering minipump, and they formed the (untreated) CHF group.
A total of 10 additional age-and diet-matched rats were injected with saline and served as controls. After 28 days, when overt heart failure had developed, animals were killed and their body weight and tibialis anterior (TA) weight were measured. Muscles were immediately frozen in liquid nitrogen and stored at Ϫ80°C. Blood was drawn for TNF␣ and AngII measurements.
Experiments were approved by the Biological Ethical Committee of the University of Padua and performed according to Italian law.
Assessment of RV Hypertrophy and Failure
To ensure that the monocrotaline-treated animals developed RV failure, left ventricular mass/RV mass (LVM/RVM) and the RV mass/RV volume index (RVM/RVV) were calculated with a computerized planimeter on photographic pictures of formalin-fixed transverse sections of the heart taken in the middle portion of the interventricular septum.
Electrophoretic Separation of MHCs
MHCs (MHC2a [fast oxidative] and MHC2b [fast glycolytic]) were separated using the previously described electrophoretic method. 3 
Assessment of MHC Distribution
The percent distribution of the MHCs was determined by a densitometric scan using a Jandel Scientific system. 3, 4, 7 Single-Fiber Cross-Sectional Area
We used single-fiber cross-sectional areas (CSA) as an index of myofiber atrophy. 7, 8 Cross cryosections were taken for histological examination and stained with hematoxylin and eosin. The fiber CSA was calculated with a computerized interactive method and expressed in m 2 by counting at least 400 fibers per specimen. 8
Assessment of Apoptosis

In Situ Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick-End Labeling
In situ terminal deoxynucleotidyl transferase-mediated dUTP nickend labeling (TUNEL) of fragmented DNA was performed on cryosections using the In Situ Cell Death Detection Kit POD (Boehringer Mannheim). Labeled nuclei were identified from the negative nuclei counterstained by Hoechst 33258 and were counted after being photographed. The total number of positive nuclei was determined by counting (at a magnification of 250ϫ) all the labeled nuclei present in the whole specimen. The number of positive nuclei was then expressed as the number of TUNEL-positive nuclei per mm 3 . 18 TUNEL-positive myofibers and interstitial nuclei were distinguished on the basis of their location on sections stained with laminin, which selectively reacts with the basal lamina. TUNEL positive nuclei within the basal lamina were taken as myonuclei. 19 Separate calculations were made for total TUNEL-positive nuclei and TUNEL-positive myonuclei.
TA Western Blot for Pro-Caspase 3, Activated Caspases 3 and 9, and Bcl-2
Western blotting was performed on 12.5 polyacrylamide gels as previously described. 7 Anti-pro-caspase 3 CPP 32 (H-277, 34 kDa) and anti-Bcl-2 (29 kDa) antibodies (Santa Cruz Biotechnology) were used with anti-rabbit alkaline phosphatase (Sigma). Anti-cleaved caspase-3 (17 kDa) and anti-cleaved caspase-9 (37 kDa) (Cell Signaling Technology) were used with anti-rabbit peroxidaseconjugated antibody and revealed by chemiluminescent substrate (SuperSignal West Pico, Pierce). The absolute values of pro-caspase 3, activated caspases 3 and 9, and Bcl-2 were calculated on the blot bands with the densitometric system described above and expressed as percent of controls.
DNA Ladder
DNA was extracted from the TA muscle as previously described. 7 The ApoAlert LM-PCR Ladder assay kit (Clontech) was used to amplify the detection of nucleosomal ladder. A total of 0.5 g of genomic DNA was used. Reaction conditions were as follows: 1 cycle at 72°C for 8 minutes, 25 cycles at 94°C for 1 minute and at 72°C for 3 minutes, and 1 cycle at 72°C for 15 minutes. Polymerase chain reaction (PCR) products were electrophoresed on 1.8% agarose gels.
Confocal Microscopy Immunofluorescence
Frozen sections were incubated with anti-activated caspase-3 antibody diluted 1:50 overnight at 4°C. Slices were then incubated with anti-rabbit Cy3-conjugated antibody for 1 hour at room temperature and analyzed by Bio-Rad confocal microscopy.
AngII Assay
AngII was measured on serum using an enzyme-immunometric assay kit from SPI-BIO.
TNF␣
TNF␣ was measured with a solid-phase sandwich ELISA using a monoclonal antibody specific for rat TNF␣ (Euroclone).
Statistical Analysis
Values are reported as meanϮSD. Student's t tests for unpaired data were used, as was ANOVA when appropriate. A 5% difference was considered statistically significant. ANOVA was also used to look at differences in TNF␣, AngII, caspases, Bcl-2, and percentage of apoptotic nuclei.
Results
Occurrence of Heart Failure in the Monocrotaline-Treated Animals
At 28 days, all the rats with monocrotaline-induced CHF showed the presence of pericardial, pleural, and peritoneal effusions at post-mortem examination ( Figure 1 and Table 1 ). LVM/RVM was 2.6Ϯ0.8 in untreated CHF rats, 3.5Ϯ0.8 in controls (PϽ0.02), 2.4Ϯ0.7 in irbesartan-treated rats (Pϭ0.0005 versus controls), and 2.0Ϯ0.5 in nifedipinetreated rats (PϭNS versus irbesartan and Pϭ0.0005 versus controls). The RV cavity was markedly dilated in all the CHF rats, as reflected by the RVM/RVV index, which was 0.24Ϯ0.18 in untreated CHF rats versus 1.10Ϯ0.7 (Pϭ0.01) in controls and 0.41Ϯ0.09 in the irbesartan-treated animals (Pϭ0.014 versus CHF and Pϭ0.04 versus controls). In the nifedipine-treated animals, we observed a RVM/RVV of 0.60Ϯ0.18, which was significantly higher than that of both controls and irbesartan-treated rats (Pϭ0.02), indicating a lower degree of dilatation.
Degree of Muscle Atrophy
The degree of TA atrophy, as measured by TA weight/body weight ratio, was 1.60Ϯ0.05 in untreated CHF rats, 1.78Ϯ0.05 in controls, 1.69Ϯ0.04 in irbesartan-treated rats, and 1.60Ϯ0.12 in nifedipine-treated rats.
TA Fiber CSA
The CSA of the TA was 1340Ϯ460 m 2 in the untreated CHF rats, 2150Ϯ350 m 2 in the controls (Pϭ0.01), 1750Ϯ300 m 2 in the irbesartan-treated rats (Pϭ0.05 versus CHF), and 900Ϯ250 m 2 in the nifedipine-treated rats (PϽ0.002 versus irbesartan group and controls; Table 1 ).
MHC Pattern
The electrophoretic pattern of the TA in the CHF animals showed a shift toward the fast glycolytic isoform (Table 2 ). In fact, MHC2a decreased from 26.4Ϯ1.5% to 18.0Ϯ3.5% (Pϭ0.005). MHC2b increased from 74.0Ϯ1.5% to 82.0Ϯ3.5% (Pϭ0.005). In the irbesartan group, MHC2a was 25.5Ϯ5.9% (Pϭ0.04 versus CHF) and MHC2b was 74.5Ϯ5.9% (Pϭ0.04 versus CHF), whereas in the nifedipine group, MCH2a was 18.7Ϯ1.7% and MCH2b was 81.2Ϯ1.7% (PϭNS versus CHF).
Count of TUNEL-Positive Nuclei
The count of the total TUNEL-positive nuclei in the TA of the control rats was 1.1Ϯ3.9 per mm 3 , whereas in the CHF rats, this percentage was higher (41.9Ϯ44.1/mm 3 , Pϭ0.04). In the irbesartan group, we found 12.0Ϯ12.9/mm 3 TUNEL-positive nuclei (Pϭ0.03 versus controls and Pϭ0.05 versus CHF). In the nifedipine group, the total number of TUNEL-positive nuclei was 56.1Ϯ43.4/mm 3 (PϭNS versus CHF and PϽ0.05 with irbesartan; Figure 2 and Table 3 ). 
Activated Caspases 3 and 9
We confirmed the occurrence of apoptosis in animals with high numbers of TUNEL-positive nuclei by testing for the presence of activated caspases 9 and 3 (the mitochondrial regulator and the executioner, respectively; Figure 3 ). Caspase 3 is detectable during the execution phase of apoptosis, when the caspase cascade leads inevitably to programmed cell death. 20 The presence of these caspases in the muscles of untreated CHF and nifedipine-treated animals, who had the highest TUNEL positivity, and their absence in controls further indicate the presence of apoptosis and suggest that mitochondria could play an important role in this process. The presence of activated caspases 3 and 9 was shown with immunoblotting ( Figures 3A and 3B) and that of activated caspase 3 was also shown with immunofluorescence and confocal microscopy ( Figure 3C ) in the CHF and nifedipine rats. These caspases were absent in controls. Note that the activation of caspase 3 occurred in some areas of myofiber cytoplasm.
DNA Ladder
In our model of CHF, in which only a small percentage of cells are apoptotic and in which apoptosis occurs asynchronously, the genomic DNA ladder may not be visible. For this reason, we used a PCR assay to amplify specifically the nucleosomal ladder. We found a positive DNA ladder only in the untreated and nifedipine-treated animals with CHF; the ladder was negative in controls ( Figure 3D ). This experiment further stresses the occurrence of apoptosis in the muscles showing TUNEL-positive nuclei.
Pro-Caspase 3
Pro-caspase 3 was significantly increased in the untreated CHF rats when compared with controls (211Ϯ87% versus 100Ϯ10%, Pϭ0.05). In irbesartan-treated rats, although the percentage of pro-caspase 3 was lower than in untreated CHF rats, it was still significantly higher than in controls (191Ϯ72%, Pϭ0.03). In the nifedipine-treated animals, the percentage of pro-caspase 3 was similar to that of untreated CHF rats (213Ϯ76%; Table 3 ).
Bcl-2
Bcl-2 was 97Ϯ12% in controls, which was similar to that in irbesartan-treated animals (94Ϯ35%, PϭNS). In the untreated CHF rats, Bcl-2 was 70Ϯ16% (Pϭ0.02 versus both controls and irbesartan; Table 3 ).
TNF␣
There was a rise in plasma TNF␣ levels in the CHF animals (139Ϯ6% versus 100Ϯ8% in controls, Pϭ0.001). In the irbesartan group, the levels did not differ from controls but were lower than those in untreated CHF rats (108Ϯ11%, Pϭ0.05). In the nifedipine-treated animals, TNF␣ levels were similar to those of untreated CHF rats (140Ϯ12%; Table 3 ).
AngII
Plasma levels of AngII in the untreated CHF, irbesartan-treated, nifedipine-treated, and control animals are shown in Table 4 . We 
Discussion
In the rat, monocrotaline induces RV hypertrophy followed by RV dilatation and CHF. In these animals, we found TA atrophy secondary to myocyte apoptosis and a shift of the MHCs toward the fast glycolytic isoforms, confirming previously published data. 5, 7, 8 The occurrence of apoptosis was confirmed by different techniques, including immunoblotting, immunohistochemistry, confocal microscopy, and DNA ladder. Activated caspases 3 and 9 were also present; this ensured that the caspase cascade, which inevitably leads to programmed cell death, was initiated. 20 Irbesartan, a drug that selectively blocks the AT 1 receptor, could not prevent RV hypertrophy in this study, as shown by an LVM/RVM index that did not differ between the irbesartan and untreated CHF groups. The occurrence of RV dilatation, however, was partially prevented. In irbesartan-treated animals, RVM/RVV was, in fact, significantly lower than in controls and higher than in untreated CHF rats. This confirms that a certain degree of compensated hypertrophy with a lower degree of failure was present in the monocrotaline-treated rats that were treated with irbesartan for 2 weeks. Therefore, we can assume that irbesartan produced only a partial improvement in the hemodynamic pattern. A similar finding was observed in the nifedipine-treated animals, in which RV dilatation was prevented to an even higher degree and a greater deal of compensated RV hypertrophy was found. Nifedipine was used to obtain favorable hemodynamic changes in a model of CHF due to pulmonary hypertension, without directly interfering with AngII receptors.
Despite their similar hemodynamic effects, irbesartan greatly differed from nifedipine in terms of biological effects. This is, in fact, the first demonstration in vivo that an AT 1 blocker can produce beneficial effects on the skeletal muscle of rats with experimental CHF. These effects could not be obtained with the calcium blocker. In irbesartan, the MHC pattern was similar to that in controls, with a partial improvement in the degree of TA atrophy (higher TA weight/body weight and larger myocyte CSA). In the nifedipine group, however, neither MHC composition nor indices of muscle atrophy were different from untreated CHF animals.
We can reasonably speculate that this effect of irbesartan on muscle atrophy is secondary to the lower levels of apoptosis. The absolute number of TUNEL-positive cells was lower in the irbesartan group when compared with untreated CHF rats. In the nifedipine-treated rats, in which apoptosis was detected at even higher levels than in untreated CHF rats, muscle atrophy was worse. Pro-caspase 3 and activated caspases 3 and 9, which are compulsory steps in the death receptor signaling pathway, were equally decreased in irbesartan-treated animals but remained high in nifedipinetreated rats. Bcl-2, which has a protective effect, was significantly higher in irbesartan-treated than in untreated CHF rats and was similar to that in controls.
The role of TNF␣ in CHF is not entirely understood. We know that in CHF, the circulating amounts of TNF␣ are increased both in humans 21 and in animal models. 7 TNF␣ blockade with specific antagonists (Enbrel) can improve the clinical status of CHF patients. 22 TNF␣ levels parallel the severity of CHF and the number of TUNEL-positive skeletal myocytes. 7 Moreover, TNF␣ is known to worsen CHF by depressing cardiac contractility. 23 Although still debated, TNF␣ has been shown to trigger apoptosis. 10 We know that in the heart, it induces the production of sphingolipids, such as sphingosine and ceramide, which are in turn mediators of apoptosis. 23, 24 In this study, TNF␣ was significantly increased in untreated CHF animals when compared with controls, and it remained high in nifedipine-treated rats. In irbesartan-treated rats, it was slightly decreased, reaching borderline significance. The TNF␣ figures, therefore, resemble those of TUNEL, pro-caspase 3, and Bcl-2 in suggesting the existence of a link between TNF␣ and apoptosis. We can only speculate why TNF␣ is decreased with irbesartan. We may hypothesize that the less compromised hemodynamics may have interfered with TNF␣ synthesis, which in CHF is linked to clinical status. 22, 23 If that was the case, even the nifedipine-treated rats, which had a similar hemodynamic improvement, should have shown a TNF␣ reduction. Therefore, we think that the interplay between TNF␣, AngII receptors, and apoptosis is much more complicated.
From the present results, we can hypothesize that the favorable effects of irbesartan on apoptosis are likely to be secondary to a direct AT 1 -mediated antiapoptotic effect rather than to hemodynamic improvements. In fact, nifedipinetreated rats, which show a similar degree of compensated RV hypertrophy with an even lower dilatation of the RV, do not exhibit any skeletal muscle change.
The role of AngII receptors on apoptosis is far from clear. Several observations suggest that AT 2 stimulation mediates apoptosis through extracellular signal-regulated kinase (ERK) inhibition, 25 ceramide accumulation, activation of mitogenactivated protein kinase phosphatase 1 (MKP 1 ) with subsequent inhibition of mitogen-activated protein kinase, and Bcl 2 dephosphorylation. 12 Apoptosis can be blocked by PD-123319 and PD-123177, 26, 27 which are specific AT 2 blockers. In contrast, some authors 26 have shown that AT 1 blockade with losartan can equally protect from apoptosis. AT 1 stimulation can lead to an increase in Fas, together with a fall in constitutive NO synthase and Blc-2 levels. Li et al 27 and Leri et al 28 have also demonstrated that myocyte stretch-induced apoptosis can be blocked by losartan, which can also increase levels of Bcl-2 and decrease levels of Bax and p53. Similar observations have been made in the hearts of spontaneously hypertensive rats. 14 The ACE inhibitor captopril reduced apoptosis in spontaneously hypertensive rats with CHF. 15 AngII-induced apoptosis can be blocked in postinfarcted, hypertrophied ventricular myocytes by AT 1 blockers, but AT 2 antagonists had no impact on these cellular events. 29 The conflict regarding whether AT 1 or AT 2 receptors mediate apoptosis can be mediated by the observation that tissues that express primarily AT 2 exhibit AT 2 -mediated apoptosis, whereas tissues that express primarily AT 1 exhibit AT 1 -mediated apoptosis. 27 Moreover, in many tissues, skeletal muscle included, the majority of physiological responses to AngII occurs through its accumulation, which is AT 1 -mediated. 30 These observations allow us to speculate on the mechanism by which irbesartan, a highly specific AT 1 blocker, may have prevented apoptosis by acting through a receptor mechanism involving the AT 1 receptor. This specific action can be brought about even in the presence of very high levels of AngII. In fact, in irbesartan-treated rats, we found a 3-to 4-fold increase in AngII, which was similar to increases in untreated CHF and nifedipine-treated rats. It may be also speculated that excessive AT 2 stimulation due to AT 1 blockade with irbesartan may reduce the number of apoptotic cells in the skeletal muscle of CHF rats. A recent observation in humans, 31 however, shows that the AT 2 gene is not expressed in the skeletal muscle of men with CHF. In the present study, AngII levels are in keeping with those in the literature, both for normal 32 and AngII blocker-treated rats, which show a 4-to 5-fold increase in AngII. CHF itself and the reflex sympathetic tone are likely to be the cause of AngII elevation in nifedipine-treated animals.
That AngII receptor blockade and ACE inhibition can have a favorable effect on skeletal muscle fiber type, MHCs, and exercise capacity has been previously demonstrated. 4 This article is a further insight into the pathophysiology of CHF myopathy, allowing speculations on the pathogenesis of this syndrome. In fact, muscle atrophy is the main "muscular" determinant of the reduced exercise capacity in CHF. This is due to the reduced muscle force and endurance 2 and to the shift toward the fast and more fatigable fibers. 1 Irbesartan has shown potential for reducing skeletal muscle apoptosis and atrophy and in protecting from the shift toward the fast MHCs, further contributing to a possible improvement in exercise tolerance and symptoms. 33 The reason for the MHC shift remains to be established, as does the interplay between AT 1 and AT 2 receptors in the genesis and prevention of apoptosis. Thus, further experiments need to be performed. The role of TNF␣ and AngII receptors, which seem to be synergistic in the induction of apoptosis, must be further investigated.
